<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961804</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2012-02</org_study_id>
    <nct_id>NCT01961804</nct_id>
  </id_info>
  <brief_title>PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma</brief_title>
  <acronym>PREVACT</acronym>
  <official_title>Phase 3 Study Comparing Preventive Reversal of Vitamine K Antagonist Versus Reversion Only in Case of Intracranial Bleeding in Patients Receiving Vitamine K Antagonist Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <brief_summary>
    <textblock>
      The occurence of a minor craniocerebral trauma in patients receiving vitamine K antagonist&#xD;
      treatment leads to a high risk of bleeding.&#xD;
&#xD;
      Current guidelines recommend to perform a CT scan, and, in case of intracranial bleeding, to&#xD;
      reverse anticoagulation with concomitant administration of prothrombin complex concentrates&#xD;
      (PCCs) and vitamin K.&#xD;
&#xD;
      However, even if a reversion is performed, the prognostic of post-traumatic intracranial&#xD;
      bleeding remain bad.&#xD;
&#xD;
      The investigators hypothesize that, for patients admitted in an emergency department after a&#xD;
      minor head trauma and receiving anticoagulant treatment, a systematic preventive reversion&#xD;
      with PCCs can lead to a significant reduction of intracranial haemorrhage and can also&#xD;
      improve the neurological prognostic of patients versus the current strategy.&#xD;
&#xD;
      PREVACT will test this hypothesis, in an open label, randomized, multicentre, clinical trial&#xD;
      involving 400 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of intracranial bleeding diagnosed in CT scan</measure>
    <time_frame>24 hours +/- 4 hours</time_frame>
    <description>This primary outcome measure will be analyse in a centralised place by two neuro-radiologist in blind of the randomised group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric measure of intracranial haemorrhage</measure>
    <time_frame>CT scan performed 24 hours +/-4 after inclusion</time_frame>
    <description>This secondary outcome measure will be analyse in a centralised place by two neuro-radiologist in blind of the randomised group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient having a decrease in their autonomy</measure>
    <time_frame>3 months</time_frame>
    <description>A loss of at least one point in the Glasgow Outcome Score Extended</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient having a systemic or neurologic ischemic attacks</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Coagulation; Intravascular</condition>
  <condition>Craniocerebral Trauma</condition>
  <condition>Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Actual recommendations</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preventive reversion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Realise a preventive reversion before performing any CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reversion</intervention_name>
    <description>Administration of prothrombin complex concentrates: KANOKAD before CT Scan</description>
    <arm_group_label>Actual recommendations</arm_group_label>
    <arm_group_label>Preventive reversion</arm_group_label>
    <other_name>KANOKAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission in an emergency departement for a recent and isolated minor head trauma with&#xD;
             at least one of the following characteristic : a period of alteration in the level of&#xD;
             consciousness, a period of loss of consciousness (&lt; 30 min), a posttraumatic amnesia,&#xD;
             persistant posttraumatic headache, repeated vomitting (at least 2 episodes) or any&#xD;
             other neurological sign such a convulsion or a localised neurological sign, wound of&#xD;
             the scalp or the face testifying of the importance of the cranial trauma...&#xD;
&#xD;
          -  Subject receiving anticoagulant treatment with anti-vitamin K for the treatment of&#xD;
             atrial fibrillation (AF)&#xD;
&#xD;
          -  Initial ED Glasgow Coma Scale (GCS) score of ≥13&#xD;
&#xD;
          -  Achievable follow up&#xD;
&#xD;
          -  Informed consent form signed by the patient or if he/she isn't able an emergency&#xD;
             inclusion can be realised.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Delay between the minor head trauma and the possible preventive PCC's administration &gt;&#xD;
             6h&#xD;
&#xD;
          -  Subject receiving anticoagulant treatment other than anti vitamin K (heparin,&#xD;
             fondaparinux, dabigatran, rivaroxaban, apixaban...)&#xD;
&#xD;
          -  Subject receiving anticoagulant treatment for other reason than a AF&#xD;
&#xD;
          -  Subject on antiplatelet treatment (except the use of low dose of aspirin (≤ 100&#xD;
             mg/day)&#xD;
&#xD;
          -  Delocalised biology INR in capillary blood &lt; 1.5 if it's available (only in&#xD;
             departement where this analyse is a usual practice)&#xD;
&#xD;
          -  Haemorrhage or suspected haemorrhage other than intracranial which could led to a&#xD;
             reversion of the anticoagulation&#xD;
&#xD;
          -  Head trauma associated with one or further potential haemorrhagic traumatic lesions&#xD;
&#xD;
          -  Subject who reject the use of products derived from human blood&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Subject with any condition that, as judged by the investigator, would place the&#xD;
             subject at increased risk of harm if he/she participated in the study&#xD;
&#xD;
          -  Subject without social security registered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROY Pierre-Marie, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TAZAROURTE Karim, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>UH Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Agen</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Chateauroux</name>
      <address>
        <city>Chateauroux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHG du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Les Sables D'Olonne</name>
      <address>
        <city>Les Sables d'Olonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Longjumeau</name>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU METZ</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chg Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Saint Brieuc</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Versailles</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

